Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
6don MSN
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
Mehmet Oz is pledging to divest from a broad portfolio of health care stocks if he is confirmed as President Trump’s pick to ...
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
24/7 Wall St. on MSN7d
AbbVie Just Paid Investors: Here’s How Much They ReceivedAbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.
Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...
GlobalData on MSN11d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0824 ET – AbbVie raises its long-term sales outlook for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback